In this study, clinical gastric tumor samples, cell-based experiments, and nude mouse models were employed to provide the first evidence that FBXW5 binds to and degrades LATS1 through the ubiquitin-proteasome pathway, ultimately inactivating the Hippo signaling pathway (Fig. 7I). Here, FBXW5 is linked to gastric neoplasm.